Superagonistic CD28 stimulation of allogeneic T cells protects from acute graft-versus-host disease

Blood

Volumn 114, Issue 20, 2009, Pages 4575-4582

  Beyersdorf, Niklas ^a   Ding, Xin ^a   Hünig, Thomas ^a   Kerkau, Thomas ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; SUPERAGONISTIC MONOCLONAL ANTIBODY CD28; UNCLASSIFIED DRUG; CD28 ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ADOPTIVE IMMUNOTHERAPY; ALLOGRAFT; ALLOGRAFT T LYMPHOCYTE TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD4+ CD25+ FOXP3+ REGULATORY T LYMPHOCYTE; CELL TRANSPLANTATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; GRAFT VERSUS LEUKEMIA EFFECT; LEUKOCYTE CULTURE; LYMPHOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; ALLOTRANSPLANTATION; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CELL DIFFERENTIATION; CYTOLOGY; FLOW CYTOMETRY; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TRANSPLANTATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 73349132995     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-04-218248     Document Type: Article

References (37)

1. Aschan J. Allogeneic haematopoietic stem cell transplantation: current status and future outlook. Br Med Bull. 2006;77-78:23-36.
2. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol. 2002;2(4):273-281.
3. Kolb HJ, Schmid C, Barrett AJ, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2004;103(3):767-776.
4. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
5. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406.
6. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versushost disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
7. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007;8(12): 1353-1362.
8. de la Rosa M, Rutz S, Dorninger H, Scheffold A. Interleukin-2 is essential for CD4+CD25+ regulatory T cell function. Eur J Immunol. 2004;34(9): 2480-2488.
9. Barthlott T, Moncrieffe H, Veldhoen M, et al. CD25+ CD4+ T cells compete with naive CD4+ T cells for IL-2 and exploit it for the induction of IL-10 production. Int Immunol. 2005;17(3):279-288.
10. Rubtsov YP, Rasmussen JP, Chi EY, et al. Regulatory T cell-derived interleukin-10 limits inflammation at environmental interfaces. Immunity. 2008;28(4):546-558.
11. Paust S, Lu L, McCarty N, Cantor H. Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease. Proc Natl Acad Sci U S A. 2004;101(28):10398-10403.
12. Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006; 177(7):4376-4383.
13. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science. 2008;322(5899):271-275.
14. Fallarino F, Grohmann U, Hwang KW, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol. 2003;4(12):1206-1212.
15. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versushost disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.
16. Trenado A, Charlotte F, Fisson S, et al. Recipienttype specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688-1696.
17. Jones SC, Murphy GF, Korngold R. Post-hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus-leukemia response. Biol Blood Marrow Transplant. 2003;9(4): 243-256.
18. Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1455-1465.
19. Lin CH, Hunig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol. 2003;33(3):626-638.
20. Beyersdorf N, Balbach K, Hunig T, Kerkau T. Large-scale expansion of rat CD+ CD25+ T(reg) cells in the absence of T-cell receptor stimulation. Immunology. 2006;119(4):441-450.
21. Gogishvili T, Langenhorst D, Luhder F, et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE. 2009;4(2):e4643.
22. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018-1028.
23. Dennehy KM, Elias F, Zeder-Lutz G, et al. Cutting edge: monovalency of CD28 maintains the antigen dependence of T cell costimulatory responses. J Immunol. 2006;176(10):5725-5729.
24. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood. 1996; 88(8):3230-3239.
25. Hill GR, Crawford JM, Cooke KR, Brinson YS, Pan L, Ferrara JL. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 1997;90(8):3204-3213.
26. Cooke KR, Hill GR, Crawford JM, et al. Tumor necrosis factor-alpha production to lipopolysaccharide stimulation by donor cells predicts the severity of experimental acute graft-versus-host disease. J Clin Invest. 1998;102(10):1882-1891.
27. Beyersdorf N, Gaupp S, Balbach K, et al. Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis. J Exp Med. 2005;202(3):445-455.
28. Slavin S, Strober S. Spontaneous murine B-cell leukaemia. Nature. 1978;272(5654):624-626.
29. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8(6):575-581.
30. Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stemcell transplantation. N Engl J Med. 2000;343(11): 750-758.
31. Legrand N, Cupedo T, van Lent AU, et al. Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in "human immune system" Rag2(-/-)gammac(-/-) mice. Blood. 2006;108(1):238-245.
32. Anderson BE, McNiff J, Yan J, et al. Memory CD4+ T cells do not induce graft-versus-host disease. J Clin Invest. 2003;112(1):101-108.
33. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol. 2008;181(4):2855-2868.
34. Zeiser R, Leveson-Gower DB, Zambricki EA, et al. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood. 2008;111(1):453-462.
35. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, Vallera DA. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia- causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 1998;160(11):5355-5365.
36. Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007;178(1):320-329.
37. Kerstan A, Hunig T. Cutting edge: distinct TCR-and CD28-derived signals regulate CD95L, Bcl-xL, and the survival of primary T cells. J Immunol. 2004;172(3):1341-1345.